Bicyclic CX3CR1 receptor agonists
US11155538B2 · kind B2 · utility
2Cited by
1References
17Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 23, 2020 |
| Grant date | Oct 26, 2021 |
| Priority date | — |
| Expiry date | Jul 23, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2602/32
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Disclosed herein are novel cycloalka[b]heteroaryl compounds having CX3CR1/fractalkine receptor (CX3CR1) agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with CX3CR1 receptor activity in animals, in particular humans.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.